Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00475800
Status:
COMPLETED
Last Update Posted:
2012-05-21
First Post:
2007-05-18
Brief Title:
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee OsteoarthritisOA
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 39-week Open-label Extension to CCOX189A2360 a 13-week Multicenter Randomized Double-blind Double-dummy Placebo-controlled Parallel Trial of 2 Different Dose Regimens of Lumiracoxib 100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od in Patients With Primary Knee Osteoarthritis Using Celecoxib 200 mg od as a Comparator
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This 39-week open label study is designed to assess long-term efficacy safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis OA of the knee who participated in the 13-week core CCOX189A2360 study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None